Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study

References

• Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsa9 Group. Quality of life of postmenopausal women in the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial after completino of 5 years’ adjuvant treatment for early stage breast cancer. Breast Cancer Res Treat 2006;100:273–284.
   PubMed Web of Science ®Google Scholar
• Antoine C, Vandromme J, Fastrez M, Carly B, Liebens F, Rozenberg S. A survey among breast cancer survivors: treatment of the climacteric after breast cancer. Climacteric 2008;11:322–328.
   PubMed Web of Science ®Google Scholar
• Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Sterns V. Practical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669–1680.
   PubMed Web of Science ®Google Scholar
• Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, Sismondi P. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45:29–38.
   PubMed Web of Science ®Google Scholar
• Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopaual breast cancer patients taking adjiuvant aromatase inhibitor therapy. Curr Oncol 2007;14:S20–S40.
   PubMedGoogle Scholar
• North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause 2007;14:357–369.
   Web of Science ®Google Scholar
• Von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone replacement therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 2005;97:533–535.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, et al Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–482.
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, et al Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–146.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Wolf SL, Barton DL, Laack NN. Symptom management in premenopausal patients with breast cancer. Lancet Oncol 2008;9:993–1001.
   PubMedGoogle Scholar
• Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomised double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969–973.
   PubMed Web of Science ®Google Scholar
• Rigg LA, Hermann H, Yen S. Absorption of estrogens from vaginal creams. N Eng J Med 1978;298:195–197.
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;Oct18;(4). CD001500.
   PubMed Web of Science ®Google Scholar
• Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovtz M. Efficacy of low-dose estradiol vaginal Tablets in the treatment of atrophic vaginitis. A randomised controlled trial. Obstet Gynecol 2008;111:67–76.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, Klein KO. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9:179–187.
   PubMed Web of Science ®Google Scholar
• Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584–587.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Rust J, Golomok S, Davis S, Bouchard C, Brown C, Basson R, Sarti CD, Kuznicki J, Rodenberg C, Derogatis L. Profile of female sexual function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause 2004;11:474–483.
   PubMed Web of Science ®Google Scholar
• Derogatis L, Rust J, Golomok S, Bouchard C, Nachtigall L, Rodenberg C, Kuznicki J, McHorney CA. Validation of the profile of female sexual function (PFSF) in surgically and naturally menopausal women. J Sex Marital Ther 2004;30:25–36.
   PubMed Web of Science ®Google Scholar
• Brizzolara S, Killeen J, Severino R. Vaginal pH and parabasal cells in postmenopausal women. Obstet Gynecol 1999;94:700–703.
   Google Scholar
• Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with typical estrogen? The Oncol 2008;13:222–231.
   PubMed Web of Science ®Google Scholar
• Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer, 2005;4:2673–2681.
   Google Scholar
• Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45–52.
   PubMed Web of Science ®Google Scholar
• Nilsson K, Heimer G. Low-dose 17β-estradiol during maintenance therapy – a pharmacokinetic and pharmacodinamic study. Maturitas 1995;21:33–38.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climateric 2005;8:83–92.
   PubMed Web of Science ®Google Scholar
• Kvorning JDN, Jensen HK. Pharmaceutical development of low-dose estradiol vagitories. Proc Int Workshop Copenhagen 1986;51–60.
   Google Scholar
• Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556–562.
   PubMed Web of Science ®Google Scholar
• Parsons A, Merritt D, Rosen A, et al Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101(2):346–352.
   Google Scholar
• Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178–180.
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259–263.
   PubMed Web of Science ®Google Scholar
• Malinovszky KM, Gould A, Foster E, Cameron D, Humphreys A, Crown J, Leonard RC; Anglo Celtic Co-operative Oncology Group. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer 2006;95:1626–1631.
   PubMed Web of Science ®Google Scholar
• Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psycho-Oncology 2004;13:295–308.
   PubMed Web of Science ®Google Scholar
• Dugal R, Hesla K, Sordal T, Aase Kh, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293–297.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005;7:1–4.
   PubMed Web of Science ®Google Scholar